ZEVRA THERAPEUTICS INC (ZVRA)
US4884452065 - Common Stock
Taking everything into account, ZVRA scores 2 out of 10 in our fundamental rating. ZVRA was compared to 196 industry peers in the Pharmaceuticals industry. ZVRA has a bad profitability rating. Also its financial health evaluation is rather negative. ZVRA is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year ZVRA has reported negative net income.
ZVRA had a negative operating cash flow in the past year.
ZVRA had negative earnings in each of the past 5 years.
In the past 5 years ZVRA reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of ZVRA (-45.53%) is comparable to the rest of the industry.
With a Return On Equity value of -202.44%, ZVRA is not doing good in the industry: 72.31% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.53% | ||
| ROE | -202.44% | ||
| ROIC | N/A |
ROA(3y)-36.67%
ROA(5y)-91.49%
ROE(3y)-57.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 111.13%, ZVRA belongs to the best of the industry, outperforming 99.49% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for ZVRA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 111.13% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZVRA has been increased compared to 1 year ago.
The number of shares outstanding for ZVRA has been increased compared to 5 years ago.
Compared to 1 year ago, ZVRA has a worse debt to assets ratio.
2.2 Solvency
ZVRA has an Altman-Z score of -3.39. This is a bad value and indicates that ZVRA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.39, ZVRA perfoms like the industry average, outperforming 41.54% of the companies in the same industry.
A Debt/Equity ratio of 1.80 is on the high side and indicates that ZVRA has dependencies on debt financing.
ZVRA has a Debt to Equity ratio of 1.80. This is in the lower half of the industry: ZVRA underperforms 77.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.8 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.39 |
ROIC/WACCN/A
WACC8.97%
2.3 Liquidity
ZVRA has a Current Ratio of 2.00. This is a normal value and indicates that ZVRA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.00, ZVRA is doing worse than 65.13% of the companies in the same industry.
ZVRA has a Quick Ratio of 2.00. This is a normal value and indicates that ZVRA is financially healthy and should not expect problems in meeting its short term obligations.
ZVRA has a Quick ratio of 2.00. This is in the lower half of the industry: ZVRA underperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
The earnings per share for ZVRA have decreased strongly by -78.72% in the last year.
Looking at the last year, ZVRA shows a very strong growth in Revenue. The Revenue has grown by 45.05%.
ZVRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.37% yearly.
EPS 1Y (TTM)-78.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220%
Revenue 1Y (TTM)45.05%
Revenue growth 3Y27.37%
Revenue growth 5YN/A
Sales Q2Q%-47.47%
3.2 Future
Based on estimates for the next years, ZVRA will show a very strong growth in Earnings Per Share. The EPS will grow by 32.05% on average per year.
Based on estimates for the next years, ZVRA will show a very strong growth in Revenue. The Revenue will grow by 61.69% on average per year.
EPS Next Y-26.71%
EPS Next 2Y23.99%
EPS Next 3Y30.09%
EPS Next 5Y32.05%
Revenue Next Year3.23%
Revenue Next 2Y81.93%
Revenue Next 3Y78.12%
Revenue Next 5Y61.69%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ZVRA. In the last year negative earnings were reported.
Also next year ZVRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ZVRA's earnings are expected to grow with 30.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.99%
EPS Next 3Y30.09%
5. Dividend
5.1 Amount
No dividends for ZVRA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ZEVRA THERAPEUTICS INC
NASDAQ:ZVRA (9/18/2024, 8:00:03 PM)
After market: 8 +0.17 (+2.17%)7.83
+0.3 (+3.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap412.01M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.53% | ||
| ROE | -202.44% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 111.13% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.8 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2 | ||
| Quick Ratio | 2 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-78.72%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-26.71%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)45.05%
Revenue growth 3Y27.37%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y